Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7
Author:
Affiliation:
1. Syros Pharmaceuticals Inc., 35 Cambridge Park Drive, Fourth Floor, Cambridge, Massachusetts 02140, United States
2. Paraza Pharma Inc., 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01171
Reference30 articles.
1. Hallmarks of Cancer: The Next Generation
2. CDK7 inhibitors as anticancer drugs
3. CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
4. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
5. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7);European Journal of Medicinal Chemistry;2024-10
2. Structure-Based Design and Development of Phosphine Oxides as a Novel Chemotype for Antibiotics that Dysregulate Bacterial ClpP Proteases;Journal of Medicinal Chemistry;2024-09-02
3. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09
4. Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design;Structure;2024-08
5. Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors;ACS Medicinal Chemistry Letters;2024-07-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3